Epizyme is a biopharmaceutical company that is focused on rewriting treatment for people with cancer and other serious diseases. The U.S. Food and Drug Administration (FDA) granted approval of TAZVERIK (tazemetostat), a selective small molecule inhibitor of the EZH2 histone methyltransferase for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. The FDA has also granted orphan drug designation to tazemetostat for the treatment of patients with malignant rhabdoid tumors, soft tissue sarcoma, mesothelioma and an orphan drug period for treatment of patients with follicular lymphoma. The EPZM stock yearly return is shown above.
The yearly return on the EPZM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the EPZM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|